NCT06971614View on ClinicalTrials.gov

A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

PHASE2RecruitingINTERVENTIONAL

Enrollment

160

Participants

Timeline

Start Date

June 9, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

May 31, 2029

Conditions

Nonmuscle-invasive Bladder Cancer

Interventions

BIOLOGICAL

T3011

T3011 will be administered at a dose of 1x10\^10 PFU intravesically.

Trial Locations (2)

33615

RECRUITING

Florida Urology Partners, LLP, Tampa

85140

NOT_YET_RECRUITING

East Valley Urology Center, Queen Creek

All Listed Sponsors

lead

ImmVira Pharma Co. Ltd

INDUSTRY

NCT06971614 - A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC | Biotech Hunter | Biotech Hunter